TWC
MDGL icon

TD Waterhouse Canada’s Madrigal Pharmaceuticals MDGL Stock Holding History

TD Waterhouse Canada’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.6K Hold
73
– – ﹤0.01% 1498
2026
Q1 		$38.5K Buy
+73
New +$34.9K ﹤0.01% 1425

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TD Waterhouse Canada's MDGL Position: Q2 2026 in Review

TD Waterhouse Canada held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 73 shares worth $37.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1498.

TD Waterhouse Canada first reported a position in MDGL in Q1 2026 and has held it in 2 quarters since. The position peaked at $38.5K in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • TD Waterhouse Canada held 73 shares of Madrigal Pharmaceuticals worth $37.6K as of Q2 2026.
  • TD Waterhouse Canada left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #1498 holding.
  • TD Waterhouse Canada first reported a position in Madrigal Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • TD Waterhouse Canada's Madrigal Pharmaceuticals position peaked at $38.5K in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.